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Objectives. We sought to examine whether the disturbed fi-
brinolytic system in patients with an acute coronary syndrome is
associated with a reduced endothelial fibrinolytic capacity.
Background. Intracoronary thrombus formation is a frequent
finding in acute coronary syndromes. Systemic alterations of
coagulation and fibrinolysis are known to occur, but possible
disturbances of endothelial fibrinolytic function have not been
investigated.
Methods. We compared 42 patients with an acute coronary
syndrome (acute myocardial infarction in 11 and unstable angina
pectoris in 31) with 25 patients with stable angina. Venous blood
was sampled serially for determination of markers of the fibrino-
lytic system and of hypercoagulability from admission to day 10.
An occlusion test to determine the maximal endothelial tissue-
type plasminogen activator (t-PA) release was also performed.
Results. Both on day 0 and day 10, patients with an acute
coronary syndrome had a marked elevation of t-PA mass concen-
tration (mean value 6 SEM 14.4 6 1.6 [day 0], 18.9 6 2.5 ng/ml
[day 10]) and of plasminogen activator inhibitor (PAI) (9.4 6 2.2
[day 0], 11.3 6 2.6 AU/liter [day 10], p < 0.05 vs. patients with
stable angina). There was also a hypercoagulative state with
elevated thrombin activity and increased D-dimers (p < 0.05 vs.
patients with stable angina). Maximal endothelial t-PA release
was initially reduced (p < 0.05 vs. patients with stable angina) to
2.3 6 0.9 ng/ml, but levels recovered during follow-up to 4.4 6 1.4
ng/ml (vs. 5.7 6 1.5 ng/ml in patients with stable angina).
Conclusions. Despite the known prolonged systemic alteration
of fibrinolysis in acute coronary syndromes, endothelial fibrino-
lytic capacity is reduced only during the acute phase and becomes
normalized during follow-up, and thus is linked more to intravas-
cular thrombus formation than to steady state levels of markers of
the fibrinolytic system.
(J Am Coll Cardiol 1998;31:547–51)
©1998 by the American College of Cardiology
Intracoronary thrombus formation is a common finding in
acute coronary syndromes. Occlusive thrombus formation is
believed to be the final event in the majority of patients with an
acute myocardial infarction. A high incidence of intracoronary
thrombi is also reported (1,2) in patients with unstable angina
pectoris. Disturbances of hemostasis and of fibrinolysis in
acute coronary syndromes have been described in several
investigations (3–6). A procoagulant state, as judged by in-
creased markers of thrombin generation and activity and by
elevated levels of fibrin degradation products, has been ob-
served (3,7). In patients with an acute coronary syndrome,
tissue-type plasminogen activator (t-PA) mass concentration
and plasminogen activator inhibitor (PAI) activity has been
found to be elevated (2–4,8). Elevation of the t-PA mass
concentration (judged by antigen determination) could be
explained by a high level of inhibitor-bound plasminogen
activator. Elevation of t-PA mass concentration was also
observed in patients with significant stable angina pectoris in
the European Concerted Action on Thrombus and Disabilities
(ECAT) study (9). In contrast to these high levels, the stimu-
lated release of t-PA from the endothelium was found not to be
disturbed in patients with stable coronary heart disease (10).
In this prospective study, therefore, we aimed to character-
ize the complex disturbances of the fibrinolytic system in the
acute and postacute phase in patients with an acute coronary
syndrome by comparing serially determined values of endothe-
lial fibrinolytic reserve with steady state levels of t-PA mass and
PAI activity and associated molecular markers of fibrinolysis
and hemostasis.
Methods
Patients and protocol. We included 42 patients with an
acute coronary syndrome in the study. These patients were
From the Medizinische Universita¨tsklinik, Tu¨bingen, Germany. This study
was presented in part at the 68th Annual Scientific Sessions of the American
Heart Association, Anaheim, California, November 1995.
Manuscript received August 5, 1997; revised manuscript received October
29, 1997, accepted November 21, 1997.
Address for correspondence: Prof. Dr. Hans Martin Hoffmeister, Mediz-
inische Universita¨tsklinik, Abteilung Innere Medizin III, Otfried-Mu¨ller-Strasse
10, 72076 Tu¨bingen, Germany.
JACC Vol. 31, No. 3
March 1, 1998:547–51
547
©1998 by the American College of Cardiology 0735-1097/98/$19.00
Published by Elsevier Science Inc. PII S0735-1097(97)00531-7
admitted to our institution because of either acute myocardial
infarction (n 5 11) or repeated periods of angina pectoris at
rest (n 5 31). Because of the severity of their disease, all
patients were initially admitted to the intensive care unit and
treated there for $24 h.
Patients with acute myocardial infarction. All 11 patients
with acute myocardial infarction had had the onset of symp-
toms within the last 12 h before admission. All 11 had
electrocardiographic alterations indicative of myocardial in-
farction (ST segment elevation .0.1 mV in at least two leads
and consecutive R wave reduction or development of a Q wave
during follow-up), and all had an increase in creatine kinase
levels during follow-up of at least three times the upper level of
the normal range in our institution, which is 80 U/liter. These
11 patients were considered ineligible for thrombolytic treat-
ment because of delayed admission (.6 h after onset of
symptoms and absence of angina pectoris), high risk of bleed-
ing, a history of complicating factors such as gastric ulcer,
cerebral hemorrhage and other risk constellations, or refusal
of thrombolytic therapy after receiving information. Therefore,
these were follow-up patients with an acute myocardial infarc-
tion within the last 12 h without thrombolytic therapy. Their
age ranged from 45 to 83 years (mean 6 SD 64 6 11). Eight of
the 11 patients of this group underwent cardiac catheteriza-
tion. Five had one-vessel disease, one had two-vessel disease
and two had three-vessel disease. Two of these patients had
diabetes mellitus, and seven were smokers.
All except 2 of the 11 patients received aspirin (100 to
300 mg/day) and all were treated with intravenous heparin
(1,000 IU/h) adjusted by repeated measurements to have
about twice the normal upper level of activated partial
thromboplastin time. Heparinization was started with an
intravenous bolus of 5,000 IU, with intravenous heparin
administration continued for 24 to 48 h. The patients then
received heparin (7,500 IU) subcutaneously twice daily.
Patients with unstable angina pectoris. Thirty-one patients
had unstable angina pectoris (Braunwald class IIIB [11] in 29
and class IIIC in 2). Sixteen patients had transient ST alter-
ations initially or during follow-up. None had an increase in
creatine kinase levels during follow-up. The treatment of these
patients was comparable to that described for the patients with
acute myocardial infarction. Additionally, these patients, like
those with acute infarction, received intravenous nitrates and
beta-adrenergic blocking agents on an individual basis. Fur-
thermore, one third of these 31 patients with unstable angina
underwent percutaneous transluminal coronary angioplasty
(PTCA) within the first 24 h because their condition could not
be rapidly stabilized by medical treatment. There was no
difference between the patients in this group with and without
PTCA at either the first or the second period of blood
sampling. All except two patients in this group underwent
coronary angiography. Fifteen patients had single-vessel dis-
ease; the other 14 had multivessel disease. The age ranged
from 36 to 78 years (mean 6 SD 60 6 10). Two of these 31
patients had diabetes and 8 were smokers.
Comparison group and normal volunteers. For comparison,
data from 25 patients with proved coronary heart disease and
stable angina pectoris were used. Data from these patients, all
with cardiac catheterization, were published recently (3). Their
demographic data and the severity of coronary artery disease
were comparable to those of our 42 patients with an acute
coronary syndrome. The age range was 34 to 72 years (mean 6
SD 55 6 9). In addition, we examined a control group of 12
healthy volunteers, none of whom had any evidence for cardiac
disease. These subjects had had no experience of cardiovascu-
lar disease during a 2-year follow-up period. They were not
age-matched (age range 21 to 26 years [mean 6 SD 23 6 1]).
All 12 volunteers were nonsmokers taking no medication.
Ethical considerations. All patients gave confirmed con-
sent for the additional blood sampling after receiving verbal
information about the study. The study protocol was approved
by the Ethics Committee of the University of Tu¨bingen.
Blood sampling and measurements. Blood sampling was
done initially and 8 to 10 days after admission. After the initial
blood sampling, we aimed to obtain all blood samples between
7 and 8 AM to minimize the effect of diurnal variation (12).
Blood was always sampled by separate venous puncture.
Venous blood was obtained in citrated 10-ml vials (10% citrate
solution, Sarstedt, Germany).
To determine the maximal endothelial t-PA release, we
performed the venous occlusion test used by Francis et al. (10).
After the baseline sample was obtained, a cuff at the upper arm
was inflated with a pressure of 100 mm Hg for 10 min and a
venous blood sample was drawn at the end of the occlusion
period. Data from this test were available from 39 patients
initially and from 20 patients on follow-up at day 10.
After sampling, the citrated blood was centrifuged for
20 min at 2,000 g at 20°C and the plasma then shock-frozen in
200-ml aliquots in liquid nitrogen. The plasma was stored
deep-frozen until the measurements were performed. For the
various determinations, commercially available kits were used
according to previously published methods (13); therefore,
only the principles of the tests are given. All assays were
performed in duplicate.
Fibrinogen was measured by using a commercially available
test kit according to the method of Clauss (Baxter).
Plasminogen was determined by using a chromogenic sub-
strate kit (Chromogenix, Mo¨lndal, Sweden). Plasma was incu-
Abbreviations and Acronyms
AU 5 arbitrary units (defined as the amount required to inhibit
1 IU of tissue-type plasminogen activator/ml of plasma)
Dt-PA 5 endothelial tissue-type plasminogen activator release
(difference between stimulated and unstimulated level)
ECAT 5 European Concerted Action on Thrombus and Disabilities
(study)
ELISA 5 enzyme-linked immunoassay
PAI 5 plasminogen activator inhibitor
PTCA 5 percutaneous transluminal coronary angioplasty
TAT 5 thrombin–antithrombin III complex
t-PA 5 tissue-type plasminogen activator
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bated with streptokinase and the chromogenic substrate
S-2251 and the extinction was compared with a standard curve
from normal plasma (Chromogenix).
The concentration of t-PA antigen was measured according
to the method of Kluft (14) by using a commercially available
kit, “coalize-t-PA” (Chromogenix). This is an enzyme-linked
immunoassay (ELISA) in sandwich technique; the sensitivity
of this test, which is highly specific for single- or double-chain
t-PA, is 0.5 ng/ml t-PA.
PAI-1 was determined by using a commercially available
chromogenic substrate test (Chromogenix). For this test,
plasma was incubated with a known amount of t-PA. Plasmin-
ogen was thereafter activated from the residual t-PA to
plasmin and incubated with the chromogenic substrate S-2403.
The activity was then given in arbitrary units (AU) that were
defined as the amount required to inhibit 1 IU of t-PA/ml
plasma.
D-dimer was measured according to Elms et al. (15) by
using a commercial sandwich enzyme-linked immuno sorbent
assay followed by a chromogenic substrate test (capture
ELISA, Boehringer, Mannheim, Germany). All chemicals and
standards were obtained from Boehringer.
The thrombin–antithrombin-III complex (TAT) was deter-
mined according to the method of Pelzer et al. (16) by using a
commercially available ELISA “Enzygnost TAT-micro” (Behr-
ing Werke, Marburg, Germany). All chemicals used and the
control and standard plasma were obtained from Behring
Werke.
Statistical evaluation. Unless otherwise indicated, all data
are given as mean value 6 SEM. Data were stored and
evaluated on a computer program (Statistical Software Pack-
age JMP; SAS Institute Inc.). Because there was no difference
between the data of patients with unstable angina pectoris and
acute myocardial infarction, these data are summarized as the
acute coronary syndrome group. Data for this group were
compared with those of the 25 patients with stable angina.
Data were tested for normal distribution by using a Shapiro-
Wilk test. In case of a nonnormal distribution, a logarithmic
transformation was performed (t-PA, PAI, D-dimer) before
further testing. An analysis of variance combined with a
Dunnett test was performed for comparison of the initial and
follow-up data of patients with an acute coronary syndrome
with the data of patients with stable angina (17). The test
hypothesis was that steady state markers were elevated in
patients with an acute coronary syndrome. Because the endo-
thelial t-PA release (i.e., difference between stimulated and
unstimulated level [Dt-PA]) data did not have a normal
distribution, a nonparametric Kruskal-Wallis test was applied.
A p value , 0.05 was set as the level of significance. Data from
the 12 volunteers were given only for orientation, as this group
was not matched for age or risk factors.
Results
Fibrinolytic system. The 42 patients with an acute coronary
syndrome had marked alterations of fibrinolysis. The t-PA
mass concentration was higher in the patients with unstable
angina pectoris or acute myocardial infarction both initially
(14.4 6 1.6 ng/ml) and 10 days later (18.9 6 2.5 ng/ml) than
that in the comparison group as in patients with stable angina
pectoris (Fig. 1). PAI activity tended to be increased on
admission and more pronounced at 10 days (9.4 6 2.2 and
11.3 6 2.6 AU/liter, respectively) in patients with unstable
angina; this pattern was similar in patients with acute myocar-
dial infarction and there was no significant difference between
these two groups. The data in Figure 1 indicate the prolonged
disturbances of the fibrinolytic system in the total group of
patients with an acute coronary syndrome, as judged from
plasma steady state levels, by comparison with values in the
patients with stable angina. This difference was evident despite
the clinical stability on day 10 of the patients with an acute
coronary syndrome. Fibrinogen levels were slightly elevated on
admission of the patients with an acute coronary syndrome and
rose further during follow-up (p , 0.01 vs. values in patients
with stable angina) (Table 1). Plasminogen and antiplasmin
levels were not different from values in the healthy control
group (Table 1).
Endothelial fibrinolytic reserve. Initially, the endothelial
fibrinolytic reserve was markedly reduced (p , 0.05) in both
groups of patients with an acute coronary syndrome (Dt-PA
2.3 6 0.9 ng/ml) despite the elevated steady state of t-PA mass
concentration in plasma (Fig. 2). During follow-up, the maxi-
mal Dt-PA became normalized in the acute coronary syndrome
group and was statistically not different from findings in
patients with stable angina (Fig. 2). Dt-PA in the patients with
stable angina was comparable to that in the healthy control
subjects.
Disturbed hemostasis. A trend to a hypercoagulative state
was present in the patients with an acute coronary syndrome
Figure 1. Levels of t-PA mass concentration and of PAI in plasma
samples of patients with an acute coronary syndrome on admission (0
d) and at 10 days (10 d) in comparison with levels in patients with
stable angina pectoris (SAP). The data demonstrate that, even after
clinical stabilization, patients with an acute coronary syndrome have
persistent elevation of both measures in comparison with values in
patients with stable angina. Values shown are mean values 6 SEM. Data
from the 12 healthy volunteers (controls) are shown for orientation.
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on admission and at 10 days. The TAT levels indicated
enhanced thrombin activation. D-dimer concentration was
increased in parallel with the activated hemostasis in patients
with an acute coronary syndrome even at 10 days of follow-up
in comparison with findings in patients with stable angina (p ,
0.05, Table 1).
Discussion
These results indicate that endothelial fibrinolytic reserve is
considerably impaired in patients with an acute coronary
syndrome. This disturbance is transient and reversible after the
acute initial phase (implying a close association with the
presence of the intracoronary thrombus in patients with an
unstable condition), whereas the alteration of the plasma
steady state levels of markers of the fibrinolysis—as indicated,
for example, by elevated t-PA antigen levels—persists despite
clinical stabilization of the patients.
Systemic alterations of fibrinolysis. Release of t-PA is an
important mechanism for the balance of thrombogenesis and
thrombolysis in the circulation (10). The endothelium is the
main source of t-PA and can release the considerable amount
of t-PA during several stress conditions (10). In patients with
coronary artery disease, Francis et al. (10) found normal t-PA
release in patients with stable angina pectoris, whereas t-PA
mass concentration was described as being elevated in patients
with stable angina. In unstable angina, normal (2) or elevated
(3,4) levels have been described. Munkvad et al. (4) observed
elevated t-PA antigen levels in patients admitted to the
hospital because of chest discomfort. Despite the absence of an
acute myocardial infarction, patients with elevated t-PA anti-
gen levels had a higher future risk for acute coronary syn-
dromes. In the ECAT study (9), t-PA antigen levels were also
elevated in patients with more pronounced coronary artery
disease. Whereas this elevated level of t-PA mass concentra-
tion was confirmed by several investigators, t-PA activity was
described to be normal or even reduced in such patients (4).
This finding results from the fact that when ELISA is used for
antigen determination, inactivated t-PA (bound to PAI) is also
determined. Thus, high t-PA antigen levels are not beneficial
but a marker for future coronary events (18) even in appar-
ently healthy men because the high levels are due to the high
PAI activity in such patients. The latter observation is in
accordance with some other studies (19) on the impact of
long-term alterations of fibrinolysis in patients at risk. Such
changes may shift the hemostatic balance to a more prothrom-
botic state (as is supported by elevated D-dimer levels [20]).
Furthermore, it may promote not only acute thrombosis but
also the development of atherosclerosis, if the meaning of
repeated subclinical thrombi for the progression of atheroscle-
rosis is taken into consideration (21). This situation may be
aggravated by a further rise in PAI and marked plaque rupture.
For PAI, a diurnal variation was described that is similar to
the diurnal variation in the incidence of acute myocardial
infarction (12). PAI activity was reported to be 1) increased in
patients with an acute coronary syndrome (2,4), 2) related to
future coronary events (5,22), and 3) still present months after
the acute phase of the coronary artery disease (23,24).
Endothelial fibrinolytic function. During the acute phase
in acute coronary syndromes, fibrinolytic endothelial function
is disturbed. One explanation for the reduced endothelial t-PA
release may be exhaustion of the release capacity due to the
considerably increased PAI activity. It might be hypothesized
Table 1. Data on the Fibrinolytic System and Hemostasis in Three Patient Groups
Patients With an Acute
Coronary Syndrome
Patients With Stable
Angina Pectoris (day 0)
Healthy Control
Subjects (day 0)Day 0 Day 10
Fibrinogen (mg/dl) 427 6 39 513 6 35* 372 6 22 270 6 7
Plasminogen (%) 120 6 4 132 6 7 125 6 6 115 6 12
Antiplasmin (%) 115 6 3 113 6 4 108 6 5 119 6 5
TAT (mg/liter) 6.5 6 1.3 7.5 6 2.8 4.9 6 0.8 5.3 6 1.4
D-dimer (ng/ml) 484 6 70 651 6 111† 358 6 52 186 6 45
*p , 0.01, †p , 0.05 by analysis of variance. Data presented are mean value 6 SEM. Day 0 5 initial blood sampling;
Day 10 5 follow-up blood sampling (at day 8 to 10); TAT 5 thrombin–antithrombin III complex.
Figure 2. Dt-PA induced by a venous occlusion test in patients with an
acute coronary syndrome on admission (0 d) and at 10 days (10 d) in
comparison with values in patients with stable angina pectoris (SAP).
The Dt-PA in patients with an acute coronary syndrome normalizes
during 10 days of follow-up and is thereafter not different from that in
patients with stable angina. Values shown are mean value 6 SEM.
Data from the healthy volunteers (controls) are shown for orientation.
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that previous high levels of PAI caused the overall systemic
reduction in endothelial t-PA, resulting in a subsequent failure
to prevent thrombotic events. In this view, the reduction in
endothelial release could be interpreted as a failure of endo-
thelial fibrinolytic capacity. This hypothesis is in accordance
with the observation of Francis et al. (10) that a trend to a
lower Dt-PA, forcing local thrombus formation, is present even
in patients with stable angina pectoris. Such a failure might be
one of the prerequisites for local thrombus formation. One
limitation of our study is the fact that all patients with an acute
coronary syndrome received aspirin and heparin. Because
there are no reported data on this issue, we cannot exclude, for
example, the possibility that heparin can influence the recovery
of endothelial fibrinolytic function. However, for ethical rea-
sons it is not possible to study a patient group without giving
this standard treatment.
The prolonged alteration of markers of the fibrinolysis, as
indicated by the elevated PAI levels, together with the hyper-
coagulative state in patients with unstable angina pectoris (3)
might be a major reason for the transition from stable to
unstable angina caused by intracoronary thrombus at a (rup-
tured) coronary plaque (25,26). The hypercoagulative syn-
drome—its presence also has some prognostic implications
(27)—and the disturbances of the fibrinolytic system, as judged
from plasma levels, do persist longer as the initial acute phase
of clinical instability. Presumably the critical balance to in-
creased thrombin activity in unstable angina (3,25–27) makes
an elevated level of fibrinolysis necessary. Therefore, an intact
t-PA release capacity during these circumstances might be
necessary to degrade the initial thrombus formation, possibly
caused by activation of the coagulation cascade. Although
Padro´ et al. (28) observed substantial levels of t-PA in athero-
sclerotic vessel wall, exhaustion of the release capacity during
acute coronary syndromes seems to result in failure of the
necessary counterpart for the known hypercoagulability due to
the prolonged activation of the coagulation cascade.
Conclusions. Our study demonstrated a transiently re-
duced systemic endothelial fibrinolytic reserve in patients with
an acute coronary syndrome compared with that in patients
with stable angina pectoris. Alterations of plasma markers of
fibrinolysis were not so closely associated with the clinical
course but persisted longer, like the reduction in systemic
endothelial fibrinolytic reserve. Testing of the fibrinolytic
reserve of the endothelium in future studies in larger patient
groups seems to be warranted to examine its value for short-
term risk stratification in patients with unstable angina pectoris.
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